THE WHAT? Pfizer introduced it’s going to purchase Metsera in a transaction valued at as much as US$7.3 billion, together with contingent funds, because it seeks to develop its presence within the quickly rising weight problems therapy market.
THE DETAILS Pfizer pays US$47.50 per share in money, a 43% premium to Metsera’s final shut, with potential milestone funds including US$22.50 per share. The deal, anticipated to shut in This fall 2025, follows Pfizer’s halted efforts to develop its personal weight problems capsule, danuglipron.
Metsera’s pipeline consists of MET-097i, a GLP-1 injectable, and MET-233i, an amylin analogue being examined each as a month-to-month monotherapy and together remedy. Early-stage outcomes for MET-233i point out a possible “best-in-class” profile, with a month-to-month dosing schedule seen by analysts as a bonus for compliance and market differentiation. Leerink Companions estimates greater than US$5 billion in peak gross sales for Metsera’s candidates.
The worldwide weight problems drug market is projected to exceed US$150 billion by the early 2030s, at present dominated by Novo Nordisk and Eli Lilly.
THE WHY? The acquisition underscores Pfizer’s have to re-establish momentum within the weight-loss class, after setbacks in its personal improvement packages, and highlights trade competitors to safe next-generation GLP-1 and associated therapies.
Supply: Pfizer
